Imugene (ASX:IMU) Sees ‘Positive Signs’ From Lung Cancer Trial, Presents Data at 2022 Global Conference – The Market Herald

Subscribe

Be the first with news that moves the market

  • Imugene (IMU) presents new data from its PD1-Vaxx trial in patients with non-small cell lung cancer at the 2022 Study of Lung Cancer annual conference in Vienna
  • The presentation was given by Professor Michael Boyer of Chris O’Brien Lifehouse Hospital
  • The study was testing its immunotherapy drug, IMU-201 or PD1-Vaxx, to determine its safety and tolerability when treating patients with non-small cell lung cancer.
  • CEO and Managing Director Leslie Chong says the company is encouraged to see ‘positive signals’ with correlative biomarker data at such an early stage of the PD1-Vaxx phase one trial
  • Imugene shares rose 5.77% to 27.5 cents per share at 1:02 p.m. AEST

Imugene (IMU) presented new data from its PD1-Vaxx trial in patients with non-small cell lung cancer at the annual conference of the International Association for the Study of Lung Cancer in Vienna.

The presentation was given by Professor Michael Boyer of Chris O’Brien Lifehouse Hospital.

The study was testing its immunotherapy drug, IMU-201 or PD1-Vaxx, to determine its safety and tolerability when treating patients with non-small cell lung cancer.

CEO and Managing Director Leslie Chong said the company was encouraged to see “positive signals” with correlative biomarker data at such an early stage of PD1-Vaxx.
Phase I trial.

“We are now progressing towards combined phase 1b studies in treatment-naïve patients.

“It is particularly gratifying to have followed a patient in the trial for more than 18 months where his tumor burden was reduced to zero.

“For a patient at such an advanced stage, having a chemotherapy-free alternative could mean a very real difference to their quality of life.”

The phase one trial included different doses, with four patients in the 10 micrograms per dose cohort, one patient achieving a complete response, meaning all signs of cancer disappeared due to treatment.

In the cohort of six patients receiving the 50 microgram dose, two achieved stable disease, meaning the tumor did not shrink or grow.

While of the four patients who received a dose of 100 micrograms

By week six, antibodies against IMU-201 were generated and maintained at high titers during treatment with 100 micrograms of PD1-Vaxx, with a dose-dependent increase in antibody production in patients receiving the dose of 100 micrograms.

Taken together, these data support further evaluation of IMU-201 in NSCLC.

Imugene shares rose 5.77% to 27.5 cents per share at 1:02 p.m. AEST.

Comments are closed.